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Background: Epstein-Barr virus associated gastric lymphoe-
pithelioma-like carcinoma (LELC) is characterized by the in-
tensive infiltration of lymphoid cells, the presence of EBV, 
and the better prognosis over typical adenocarcinoma. Thus, 
it was assumable that viral latent proteins may be respon-
sible for the recruitment of a certain T cell repertoire to 
EBV-associated gastric carcinoma. Methods: To examine 
above possibility, EBV gene expression in gastric carcinoma 
tissues and usage of TCR among the tumor infiltrating lym-
phocytes were analyzed. Results: EBV specific DNA and 
EBERs RNA were detected in 4 out of 30 patients. RT-PCR 
analysis revealed that all 4 of EBV-positive tumor tissues ex-
pressed EBNA1 mRNA and BARTs and LMP2a was detected 
only one sample out of 4. However, the EBNA2 and LMP-1 
transcripts were not detected in these tissues. CD8＋ T cells 
were the predominant population of infiltrating lymphocytes 
in the EBV-positive gastric carcinoma. According to spectra 
type analysis of infiltrating T cells, 10 predominant bands 
were detected by TCR Vβ CDR3 specific RT-PCR from 4 
EBV-positive tumor tissues. Sequence analysis of these 
bands revealed oligoclonal expansion of T cells. Conclusion: 
These findings suggest that clonally expanded T cells in vivo 




Epstein-Barr virus (EBV) is a DNA virus that belongs to the 
Herpesviridae family and infects more than 90% of the entire 
world population. EBV causes infectious mononucleosis, and 
is related to lymphocyte and epithelial cell origin tumors such 
as Burkitt’s lymphoma, lymphomas associated with im-
munocompromised patients, and undifferentiated nasophar-
yngeal carcinoma (NPC). EBV persists asymptomatically in 
lifelong carriers due to a balance between its capability to 
transform B cells into proliferating lymphoblasts and a tight 
control of EBV＋ B cells mainly by CD8＋ T cells (1). Different 
forms of EBV latency are recognized, and these are defined 
by the extent of latent viral gene expression. On initial EBV 
infection, and in latently infected lymphoblastoid cell lines in 
culture, the full spectrum of EBV latency genes, EBV nuclear 
antigen 1 (EBNA1), EBNA2, EBNA3A, EBNA3B, EBNA3C, 
EBNA-LP, latent membrane protein 1 (LMP-1), LMP-2A, 
LMP-2B, and BamHI A rightward transcripts (BARTs), is ex-
pressed and this expression pattern has been termed latency 
III. EBV-associated tumors demonstrate a third pattern of la-
tency-gene expression (latency I/II) in which only EBNA-1 
and the BamHI-A rightward transcripts are expressed (latency 
I) or there is variable expression of the latency membrane 
proteins LMP-1, LMP-2A, and LMP-2B in addition to EBNA-1 
and the BamHI-A rightward transcripts (latency II) (2-4).
  Tumor cells in virus-associated tumors express viral anti-
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gens, and cytotoxic T lymphocytes (CTLs) responding to 
these antigens destroy the tumor cells (5). CTLs responding 
to EBV-specific proteins are induced by EBV infection or re-
activation and these CTLs contribute to preventing EBV from 
proliferating within the body (6). In vitro CTL clonal ex-
pansion for BARTs suggests that EBV antigens with weak anti-
genicity could also induce EBV antigen-specific cell-mediated 
immunity (7). However, EBV antigen-specific cell-mediated 
immunity is prevented by either suppressing the expression 
of EBV antigens having strong antigenicity such as EBNA3A, 
and EBNA3C in EBV-associated tumors or self-inhibition of 
translation and antigen presentation by EBNA1 (8,9).
  It was reported that EBV genomes are present and ex-
pressed in patients with gastric carcinoma (10,11). Despite 
the fact that only 6.9∼16% of all gastric cancer cases are EBV 
positive, EBV is detected in more than 85% of lymphoepithe-
lioma-like gastric carcinoma (LELC), in which lymphocyte in-
filtration is frequently seen (12,13). LELC whose lesions are 
mostly composed of lymphocytes is epithelial cell in origin 
but morphologically similar to lymphoma. LELC comprises 2% 
of all gastric cancer cases (14) Because the prognosis for 
LELC is good and most infiltrating lymphocytes are CD8＋ T 
cells (15), it can be speculated that EBV specific proteins ex-
pressed in LELC would act as the antigens to induce the ex-
pansion of specific CTLs and that cell-mediated response by 
proliferated CTLs would affect tumor prognosis (16).
  We investigated the expression of EBV genes in EBV-asso-
ciated gastric carcinoma tissues and the presence of clonally 
expanded infiltrating T lymphocytes in cancer tissues by de-
tecting the presence of the EBV genome and by measuring 
the TCR Vβ CDR3 usage in gastric cancer tissue samples ob-
tained from 30 patients. We found expression of EBNA1 and 
BARTs in 4 cases. By measuring the length of the TCR Vβ 
CDR3 gene of CD8＋ T lymphocytes that have infiltrated into 
gastric cancer tissues and by conducting sequence analysis of 
these genes, we also found the possibility that the infiltrating 
lymphocytes EBV-associated gastric carcinomas resulted from 
the clonally expanded CD8＋ T lymphocyte population.
MATERIALS AND METHODS
Gastric carcinoma tissues and cell lines
We examined 30 samples of primary gastric carcinoma re-
sected from randomly selected Korean patients including 21 
males and 9 females whose ages ranged from 34∼76 years 
old. The positive and negative controls used for EBV gene 
expression were EBV positive B lymphoblastoid cell line and 
the gastric carcinoma cell line, MKN45, respectively. Cells 
were cultured in RPMI 1640 medium (Gibco BRL) containing 
10% fetal bovine serum (Gibco BRL), 100 U/ml of penicillin 
and 100μg/ml of streptomycin (Gibco BRL).
EBV detection
DNA PCR was performed using the primers SL18 (5’-GGC-
GCACCTGGAGGTGGTCC-3’) and SL19 (5’-TTTCCAGCAG-
AGTCGCTAGG-3’) to the variable number of tandem repeat 
(VNTR) in a mixture of 2μl of 5 mM dNTP, 1.25 U Taq poly-
merase (Perkin Elmer, Branchburg, NJ) and 10 pmol primer 
set. PCR was done in a thermal cycler (Perkin Elmer) by car-
rying out the reaction in 35 cycles of 30 sec at 94oC, 30 sec 
at 55oC, and 30 sec at 72oC with 10 min. extension at 72oC. 
The resulting PCR product was electrophoresed in 2% agarose 
gel and observed using an UV transilluminator after staining 
with ethidium bromide.
  EBV-encoded small nonpolyadenylated RNAs (EBERs) con-
stitutively expressed in EBV infected cells were used as the 
probe for in situ hybridization. Each of the 6μm tissue sam-
ples was placed on a sialine coated slide, left for 30 min at 
56oC, and placed in xylene twice for 3 min each to remove 
paraffin. The tissue sample was then placed twice in 99% and 
95% ethyl alcohol solutions for 3 min each and hydrated by 
leaving the sample in distilled water. It was then reacted in 
Proteinase K (Sigma, St. Louis, MO) at 37oC for 10 min, wash-
ed in distilled water, and completely dried by exposing to 
air for 20 min. After 40∼100μl FITC-labeled EBERs probe 
(Dako, Denmark) was placed on the dried tissue sample, it 
was reacted at 37oC for 2 h. The sample was placed in tris 
buffered saline (0.1 M Tris in normal saline; TBS) for 5 min 
and washed 3 times in TBS containing 0.1% Triton X-100. 
After 100μl anti-FITC (Dako) was placed onto the sample 
slide, the sample was reacted for 30 min at room temper-
ature, washed with TBS, reacted with alkaline phospha-
tase-conjugated anti-mouse Ig for 30 min, and stained with 
BCIP/NBT.
  In order to determine the type of EBV, PCR was performed 
using EBNA3C specific primers (sense: 5’-AGAAGGGGAGCG-
TGTGTTGT-3’, antisense: 5’-GGCTCGTTTTTGACGTCGGC- 
3’). The EBV type was determined based on the fact that type 
1 EBV would have an internal deletion at 93 bp, unlike type 
2 EBV, so the PCR product of type 1 EBV would be 153 bp, 
while that of type 2 EBV would be 246 bp (17).
  Reverse transcriptase-polymerase chain reaction (RT-PCR) 
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was performed to determine the expression of EBV specific 
genes in gastric cancer tissues. RNA was extracted using the 
RNeasy kit (Qiagen, Valencia, CA). A 30μl reaction mixture 
was prepared by adding 5μg RNA, 2μg oligo-dT primer 
(Pharmacia, Uppsala, Sweden), 2μl 10 mM dNTP 
(Boehringer Mannheim, Mannheim, Germany), 6μl 5× re-
verse transcriptase buffer, 200 U M-MLV reverse transcriptase 
(Gibco BRL). cDNA was synthesized at 42oC for 60 min. 
RT-PCR was performed using the synthesized cDNA as the 
template and the primer specific for each gene (18).
Immunohistochemistry
Immunohistochemistry was performed using anti-CD4, an-
ti-CD8, and anti-CD20 antibodies to confirm the distribution 
of infiltrating T lymphocytes and B lymphocytes into gastric 
carcinoma in paraffin-embedded tissue sections. After leaving 
6μm of gastric carcinoma tissue sample on a sialine-coated 
slide, paraffin was removed. Add each primary antibody con-
jugated to alkaline phosphatase was placed onto the slide, 
the sample was reacted at 37oC for 1 h and stained with 
BCIP/NBT. 
CDR3 length analysis
For TCR Vβ CDR3 RT-PCR, the β chain constant region (Cβ: 
5’-TTCTGATGGCTCAAACAC-3’) was used as the antisense 
primer and a specific primer corresponding to each Vβ fam-
ily was used as the sense primer (19,20). PCR was performed 
using 4μl 1.25 mM dNTP, 1.25 U Taq polymerase (Perkin 
Elmer), and 10 pmol Vβ family specific primer and Cβ pri-
mer using cDNA synthesized from RNA extracted from gastric 
carcinoma tissues. PCR was performed by carrying out the 
reaction in 30 cycles of 30 sec at 94oC, 30 sec at 55oC, and 
30 sec at 72oC, and extension was done at 72oC for 10 min. 
After confirming the PCR product by electrophoresis in a 2% 
agarose gel, it was used as the nested-PCR template to de-
termine the TCR Vβ family. Nested-PCR was performed us-
ing 1μl TCR Vβ PCR product, 1 pmol sense Vβ primer, 
and 32P-labelled antisense Cβ primer. After electrophoresis 
of the PCR product in a sequencing gel, the gel was dried 
and exposed to Fuji Super HR-G X-ray film (Fuji Photo Film 
Co., Tokyo, Japan). The band intensity of each Vβ specific 
RT-PCR product was measured using the image plate and the 
predominant band was defined when the intensity of a single 
band was more than 1/3 of the total intensity. The predom-
inant bands considered to be specific T lymphocyte clonal ex-
pansion were cut and extract DNA. PCR was performed with 
the extracted DNA using the same Vβ primer and Cβ pri-
mer, and the PCR products were confirmed using electro-
phoresis in a 2% agarose gel. PCR products of DNA extracted 
from the gel were cloned in pT7Blue-T vector (Novagen, La 
Jolla, CA), and the nucleotide sequences were analyzed. At 
the same time, direct sequencing analysis was done using the 
PCR product by using the AmpliCycle sequencing kit (Perkin 
Elmer). The nucleotide sequences of at least 4 of the clones 
that were cloned into the pT7 Blue-T vector were analyzed. 
Clonal expansion of a specific T lymphocyte was defined 
when the clone showing the same result as the direct se-
quencing of the PCR product was present in more than 2/3 
of the total clones. The BLAST server by NCBI was used for 
Nucleotide database searching and computation.
RESULTS
Detection of the EBV genome in gastric carcinoma tis-
sue samples
PCR was performed using DNA extracted from gastric carci-
noma tissue samples to confirm the presence of the EBV ge-
nome using EBV VNTR specific primers. The EBV genome 
was contained in gastric tissue samples obtained from 4 
(#967, #974, #1010, and #1016) out of 30 patients (13.3%) 
(Fig. 1A). The fact that the VNTR PCR products of 4 tissue 
samples were seen as a single band (Fig. 1B) means that each 
case of gastric carcinoma was infected with a single EBV 
clonotype. As for VNTR, each EBV strain could have a differ-
ent number of tandem repeats. Gastric carcinoma tissues with 
detected EBV genomes were undifferentiated adenocarcino-
mas according to H-E staining in which severe infiltration of 
lymphocytes was seen around the gastric carcinoma cells 
(Fig. 2A). Two (#967, #1016) of the 4 samples with the EBV 
genome were confirmed as LELC. According to the EBV 
EBER-1 in situ hybridization results, EBV genomes were ob-
served in the nuclei of gastric carcinoma cells but not in the 
connective tissues and infiltrating lymphocytes (Fig. 2B).
Types of EBV detected
To investigate the types of EBV infecting gastric carcinoma 
tissue samples with detectable EBV genomes, PCR was per-
formed using EBNA3C specific primers. The EBNA3C gene 
shows the most significant difference between Type 1 and 
Type 2, in which an internal deletion is present in Type 1 
EBV (17). The PCR product of Type 1 EBV was153 bp, and 
that of Type 2 EBV was 246 bp. The PCR results from all 
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Figure 1. Detection of EBV DNA in gastric carcinoma tissues using
PCR. (A) DNA was extracted from 30 gastric carcinoma tissue 
samples, and PCR was performed using the EBV specific primers SL18
and SL19. PCR products were electrophoresed in a 2% agarose gel.
The EBV genome was detected in 4 of the samples (#967, #974, 
#1010, and #1016). No EBV genome was detected in the gastric 
carcinoma cell line, MKN45 (negative control), and 26 gastric 
carcinoma tissue samples. Lane 1: DNA size marker, 1 kb DNA 
ladder; MKN45: gastric carcinoma cell line showing no EBV infection;
967, 974, 1010, 1016: Gastric carcinoma tissues samples with the 
EBV genome. (B) VNTR DNA of EBV LMP1 was amplified and 
electrophoresis was performed. M: DNA size marker, 100 bp DNA
ladder; DW: distilled water; MKN45: gastric carcinoma cell line 
(negative control); LCL: B lymphoblastoid cell line (positive control) 
transformed with EBV produced with the B95.8 cell line; 967, 974, 
1010, 1016: gastric carcinoma tissue samples with EBV genes 
detected.
Figure 2. Pathological findings of gastric carcinoma tissue samples and EBER in situ hybridization. (A) The pathological findings of gastric carcinoma
tissue sample #967 containing the EBV genome. This carcinoma was an undifferentiated adenocarcinoma and shows severe infiltration of 
lymphocytes (H-E staining, ×400 magnification). (B) EBERs in situ hybridization. Nuclei of gastric carcinoma cells show a positive response, 
while lymphocytes infiltrating the gastric carcinoma tissues and the surrounding connective tissue show a negative response. 
Figure 3. Determination of EBV type in gastric carcinoma tissues. PCR
was performed using EBNA3C specific primers in order to determine
the type of EBV in gastric carcinoma tissues. The resulting PCR 
product was electrophoresed. Lane 1: DNA size marker, 100 bp DNA
ladder; MKN45: negative control; B95.8: positive control; 967, 974, 
1010, and 1016: gastric carcinoma tissue samples with EBV genes 
detected.
four samples showed the same size PCR product as that iso-
lated from the B95.8 Type 1 EBV (Fig. 3), suggesting that 
all 4 samples were infected with Type 1 EBV.
Expression of EBV gene in gastric carcinoma tissue 
samples
To determine the type of latent infection present in gastric 
carcinoma tissues, which contain the EBV genome, the ex-
pression profile of EBV latent genes was investigated using 
RT-PCR. EBNA1, which is the most important for the main-
tenance of the EBV episome, was expressed in all 4 samples. 
The EBNA1, which is the gene that is expressed in all types 
of latent infection and that controls DNA replication of the 
EBV episome, was present in all samples. BARTs, which are 
usually expressed during EBV infection was detected in all 
4 samples. LMP2a was expressed in one sample (#967) out 
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Figure 4. Detection of EBV specific gene transcripts in gastric 
carcinoma tissue samples using RT-PCR. Total RNA was isolated from
gastric carcinoma tissues and cDNA was prepared. RT-PCR was 
performed using the cDNA as template and specific primers for EBV 
genes, i.e., EBNA1, EBNA2, BARTs and LMP-1. The resulting products
were electrophoresed in a 2% agarose gel. MKN45: negative control;
LCL: B lymphoblastoid cell line (positive control) transformed with 
EBV produced with the B95.8 cell line; 967, 974, 1010, 1016: gastric
carcinoma tissue samples with EBV gene detected. 
Figure 5. Distribution of lymphocytes infiltrating in gastric carcinoma tissues. Immunohistochemical staining of gastric carcinoma tissue #967
using anti-CD8 (A), anti-CD4 (B), and anti-CD20 (C) antibodies (200×).
of 4 samples. EBNA2 was not expressed in all 4 samples, sug-
gesting that the C and W promoters were not activated. 
Because EBNA2, EBNA-LP, EBNA3A, EBNA3B, and EBNA3C 
expression is controlled by the C and W promoters, they 
were not expressed, either. LMP-1, expressed during Type 2 
EBV latent infection, was not expressed (Fig. 4).
Distribution of infiltrating lymphocytes in gastric car-
cinoma tissues
Immunohistochemistry was performed using anti-CD4, an-
ti-CD8 and anti-CD20 antibodies to investigate the distribution 
of lymphocytes infiltrating EBV-positive gastric carcinoma tis-
sue samples. Most lymphocytes were stained by anti-CD8 an-
tibodies (Fig. 5A) but not with anti-CD4 and anti-CD20 anti-
bodies (Fig. 5B and C), suggesting that most lymphocytes in-
filtrating gastric carcinoma tissues were CD8＋ T cells.
T cell clonality having specific TCR Vβ chain in CD8＋ 
T cells infiltrating gastric carcinoma tissues 
Since the lymphocytes infiltrating gastric carcinoma tissues 
that contain the EBV genome were CD8＋ T lymphocytes, 
TCR Vβ chain usage was analyzed to determine the presence 
of clonal expansion according to each Vβ family in order 
to determine whether single clonal or oligoclonal T lympho-
cytes recognizing a specific antigen were expanded. After 
performing RT-PCR with Vβ family specific primers, electro-
phoresis was done in a sequencing gel and CDR3 was sorted 
according to the different sizes (Fig. 6). After the band in-
tensity of each RT-PCR product was measured according to 
each Vβ family, the predominant band was defined when 
the intensity of a single band was more than 1/3 of the total 
intensity. The predominant band was observed in Vβ family 
2, 6 and 11 of T lymphocytes infiltrating sample #967; Vβ 
family 12 and 14 of sample #974; Vβ family 3, 6, 8, and 
15 in sample #1010; and in Vβ family 8 of sample #1016. 
DNA was extracted from a total of 10 predominant bands and 
its nucleotide sequence was determined by using PCR-direct 
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Figure 6. TCR Vβchain usage of DR3 of CD8＋ T cells infiltrating gastric carcinoma tissues. After performing RT-PCR using specific primers
to each Vβ family, electrophoresis was done in a sequencing gel and CDR3 was divided according to sizes. The predominant band (arrow)
could be observed in Vβ family 2, 6, and 11 of sample #967; Vβ family 12 and 14 of sample #974; Vβ family 3, 6, 8, and 15 of sample 
#1010;Vβ family 8 of sample #1016. 967, 974, 1010, and 1016: Gastric carcinoma tissue samples with EBV gene detected.
Table I. Amino acid sequence and CDR3 length of TCR Vβ chain of CD8 T cells infiltrated to gastric carcinoma
Sequence CDR3 
length
Frequency of the 
same sequence 
among PCR clonesV CDR3 J C
#967
  Vβ2 Jβ1.1 CS VFGFEMNTEAF FGQGTRLTVV EDLNKVFPP 9 4/4
  Vβ6 Jβ2.3 CASS LGIAGPTDTQY FGPGTRLTVL EDLKNVFPP 11  8/11
  Vβ11 Jβ2.3 CASS GTSGTADTQY FGPGTRLTVL EDLKNVFPP 10 12/12
#974
  Vβ14 Jβ1.5 CAS RGTGWEYQPQH FGDGTRLSIL EDLNKVFPP 10 6/7
#1010
  Vβ8 Jβ2.3 CASS RGGVDTQY FGPGTRLTVL EDLNKVFPP 8 3/4
sequencing and also by cloning the PCR product with pT7 
Blue-T vector at the same time. The two results were then 
compared. The nucleotide sequence of at least 4 clones that 
were cloned with pT7 Blue-T vector was analyzed. A specific 
T cell clone was expanded when the clone was more than 
2/3 of the total clones showing the same result as the direct 
sequencing of the PCR product. Among the selected predom-
inant bands, the nucleotide sequence obtained by direct se-
quencing was the same as the sequence obtained from the 
pT7 Blue-T vector with Vβ CDR3 cloned into it in all cases 
except for Vβ 12 of sample #974; Vβ 3, 6, and 15 of sample 
#1010; and Vβ 8 of sample #1016. The amino acid se-
quences deduced from these samples are shown in Table I. 
The length of CDR3 was determined by subtracting 4 amino 
acids from the number of amino acids present between the 
C-terminal cysteine in the Vβ region and the first glycine 
present on glycine/X/glycine in the J region. The CDR3 
length was between 8 and 11, falling in the normal range 
of TCR Vβ CDR3. Its average was 9.6, which is similar to 
9.5, the average length of TCR Vβ. When the Vβ family 
gene was searched using BLAST to confirm Jβ and C family, 
the result showed 3 clones using the same Jβ 2.3 TCR. 
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Arginine was synthesized by N-addition in the V-D region of 
TCR Vβ of T lymphocytes infiltrating gastric carcinoma tissue 
samples #974 and #1010.
DISCUSSION
Gastric carcinoma is one of the most prevalent carcinomas 
in the world and is the most frequent carcinoma in Far East 
Asian countries such as Korea and Japan. Many studies re-
ported various indirect evidences that EBV plays an important 
role in EBV-associated gastric carcinoma (21,22). Further-
more, EBV-associated gastric carcinoma, which has a good 
prognosis, shows some p53 mutations, which are frequently 
seen in stomach cancer (23), and severe infiltration of lym-
phocytes into tumor tissues (16,24). According to previous 
studies, EBV is crucial for malignant transformation in EBV-as-
sociated gastric carcinoma (25). At the same time, we could 
assume that EBV would enable the T lymphocytes of the host 
to recognize transformed tumor cells. Therefore, we de-
termined the presence of EBV specific gene expression in 
EBV-associated gastric carcinoma and lymphocytes infiltrating 
into the tumor cells were clonal expansions of CD8＋ T 
lymphocytes.
  EBV-associated gastric carcinoma accounts for 6.9∼16% of 
all cases of gastric carcinoma (10). We found the EBV ge-
nome in 4 (13.3%) of the 30 gastric carcinoma tissues sam-
ples. According to another study investigating the presence 
of the EBV genome in gastric carcinoma cases among 
Koreans, the EBV genome was detected in 13.5% of all gastric 
carcinoma cases (26). We found similar result in this study. 
According to histopathologic findings of gastric carcinoma tis-
sue samples containing the EBV genome, the tissues were 
poorly differentiated and were severely infiltrated with lym-
phocytes. According to EBERs in situ hybridization, no EBV 
genome was detected in the surrounding lymphocytes. Thus, 
these results indicate that EBV was present in gastric carcino-
ma cells rather than in infected lymphocytes that infiltrated 
the gastric carcinoma. EBV can be largely divided into two 
types (Type 1 and Type 2), which have a slightly different 
gene composition (17). The distribution of these two types 
is similar in healthy individuals. However, most of the EBV 
isolated from tumors is Type 1, so that Type 1 EBV is more 
involved in tumorigenesis compared with Type 2 (27). EBV 
detected in all 4 samples in this study was also Type 1.
  EBV is associated with many tumors and latent infection 
could be divided into 3 different types classified according 
to the specific genes expressed in the tumor cells (2). The 
expression of EBNA1, LMP-2 and BARTs were previously re-
ported in EBV-associated gastric carcinoma (28). In this study, 
we observed the expression of only EBNA1, LMP-2 (1/4) and 
BARTs and no expression of EBNA2, suggesting that the C 
and W promoters are not activated. Furthermore, we did not 
observe the expression of LMP-1. Although EBNA1 expressed 
in Type 1 latent infection is expected to play an essential role 
in malignant cell transformation, the mechanism involved in 
this process has not been elucidated.
  According to immunohistochemistry and sequence analysis 
of the TCR Vβchain of CDR3, we found that there was an 
expansion of 5 specific T lymphocyte clones. It was likely 
that these clones were expanded tumor-specific CD8＋ T lym-
phocytes, suggesting that tumor specific antigens are present 
in EBV-associated gastric carcinoma and that CD8＋ T lym-
phocytes responding to these antigens have infiltrated tumor 
tissues. Thus, the good prognosis of EBV-associated gastric 
carcinomas could be accounted for by these CD8＋ T lympho-
cytes that result in tumor-specific cytotoxicity. The fact that 
we could not observe the same TCR clonal expansion in 3 
samples suggests that CD8＋ T lymphocyte clonal expansion 
did not respond to superantigens. This is in contrast to results 
reported previously that lytic cycle specific proteins would 
function as superantigens to expand CTL clone at the time 
of primary EBV infection (29). We observed various CD8＋ 
T lymphocyte clonal expansions possibly because antigens 
expressed during latent infection are conventional antigens 
and specific CD8＋ T lymphocytes would recognize various 
antigenic peptides originating from EBV proteins that form 
complexes with MHC class I molecules. In this study, we 
found that CD8＋ T lymphocytes infiltrated EBV-associated 
gastric carcinoma cells and that EBNA1, LMP2a and BARTs 
were expressed. This suggests that EBNA1, LMP2, or BARTs 
could provide the antigens that result in the expansion of 
CD8＋ T lymphocytes. Since EBNA1 has the Gly-Ala rich do-
main that prevents antigen processing and presentation, 
EBNA1 is not immunogenic to Human CD8＋ T cell (30). 
However, it was reported that Human CD4＋ T cells con-
sistently respond to the EBNA1, and BARTs LMP2a could act 
as an antigenic determinant in NPC and HD (7,31,32).
  We detected the presence of the EBV genome, specifically 
Type 1 EBV, in gastric carcinoma tissues. We observed the 
expression of EBNA1, LMP2a and BARTs in gastric carcinoma 
tissue samples that have the EBV genome but found no ex-
pression of EBNA2 and LMP-1. We found that lymphocytes 
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infiltrating in gastric carcinoma tissues in EBV-associated gas-
tric carcinoma were CD8＋ T lymphocyte clones responding 
to specific conventional antigens. We determined this by 
measuring the length and analyzing the nucleotide sequence 
of TCR Vβ CDR3 of T lymphocytes that have infiltrated gas-
tric carcinoma tissues. This result suggests that EBV-specific 
proteins act as antigens in EBV-associated gastric carcinoma 
to induce a cell-mediated immune response. Further in vitro 
CTL proliferation studies using EBV-specific proteins are 
needed to determine specific epitopes.
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